Alzheimer's disease (AD) and Parkinson's disease (PD) are genetically heterogeneous. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) genes may modify the risk of these disorders. We investigated whether common polymorphisms present in these genes operate as risk factors for AD and PD in Finnish subjects, independently or in concert with the apolipoprotein E 4 allele (APOE 4). Eighty late onset sporadic AD patients, 53 PD patients (34 of whom had concomitant AD pathology), and 67 control subjects were genotyped for the insertion (I)/deletion (D) polymorphism of DCP1 and the K variant of BCHE. In logistic regression analysis, the DCP1 *I allele in combination with APOE 4 significantly increased the risk of AD (OR 30.0, 95% CI 7.3-123.7), compared to subjects carrying neither of the alleles. Similar analysis showed that the risk of AD was significantly increased in subjects carrying both the BCHE wild type (*WT/ *WT) genotype and 4 (OR 9.9, 95% CI 2.9-33.8), compared to those without this BCHE genotype and 4. Further, the risk of PD with AD pathology was significantly increased for carriers of DCP1 *I and 4 (OR 8.0, 95% CI 2.1-31.1). We thus conclude that, in Finns, interaction between DCP1 *I and 4 increases the risk of AD as well as of PD with coexisting Alzheimer pathology, which underlines the importance of the DCP1 I/D polymorphism in the development of Alzheimer neuropathology, whereas the wild type BCHE genotype in combination with 4 had a combined eVect with regard to the risk of AD. (J Med Genet 2000;37:766-770) 
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most frequent neurodegenerative disorders with heterogeneous aetiologies including genetic factors. Mutations in the amyloid precursor protein and the presenilin genes are known to cause familial forms of AD, 1 whereas the -synuclein and parkin genes, when mutated, are responsible for rare familial cases of PD. 2 Furthermore, the 4 allele of apolipoprotein E (APOE 4) has been identified as the most significant risk factor for late onset familial and sporadic AD. 3 In PD, the frequency of APOE 4 has been found to be increased in cases with concomitant AD pathology. 4 Since a significant proportion of sporadic AD patients have no 4, other genetic factors must play a role in the pathogenesis of the disorder. It has also become evident that genetic polymorphisms may contribute to the development of PD. 5 6 Genes encoding dipeptidyl carboxypeptidase 1 (DCP1) (also known as angiotensin I converting enzyme (ACE)) and butyrylcholinesterase (BCHE) may modify the risk of these disorders. The deletion (D) allele of the insertion/deletion polymorphism of the DCP1 gene has been reported to be associated with longevity, 7 whereas the insertion (I) allele has recently been found to confer susceptibility to AD, 8 while neither allele has so far been observed to be associated with PD. 9 The K variant of the BCHE gene has been implicated in both AD 10 and PD. 11 Verification of the contribution of these two genes to AD and PD requires their examination for association with these disorders in diVerent populations. Our purpose here was to establish whether the DCP1 I/D and BCHE WT/K polymorphisms operate as risk factors for AD and PD in Finnish subjects, independently or in conjunction with APOE 4.
Materials and methods
Approval for the study was obtained from the local Hospital Ethical Committees. All patients and control subjects enrolled in the investigation were from the western part of Finland. The AD group consisted of 80 late onset (>65 years) sporadic patients (51 women, 29 men). Twenty seven patients (mean age at onset 73.5 years (SD 6.0)) had a clinical diagnosis of probable AD made according to the NINCDS-ADRDA criteria, 12 while for 53 cases (mean age at death 80.4 years (SD 5.5)) the clinical diagnosis had been confirmed neuropathologically using the CERAD criteria. 13 The PD group comprised 53 neuropathologically verified patients (27 women, 26 men; mean age at death 75.9 years (SD 6.3)). The pathological diagnosis of PD was based on the loss of pigmented neurones in the substantia nigra with gliosis, pigment phagocytosis, and Lewy bodies. The PD cases were divided into diVerent groups according to the CERAD criteria. 13 Thirty four PD cases yielded histological findings suggestive (group B) or indicative (group C) of AD (referred to as the PD(B+C) group), whereas 13 showed no histological evidence of AD (group 0). In the remaining six PD cases, the evidence for AD was uncertain (group A, n=3) or no information was available on possible concomitant AD pathology (n=3). The 67 controls were elderly subjects with no clinical signs of neurological or psychiatric disease (30 women, 37 men; mean age 75.9 years (SD 7.3)). In 59 cases, brain tissue had been obtained at necropsy and verified to be normal based on a thorough neuropathological investigation made according to CERAD recommendations. 13 Amygdala, hippocampus (CA 1 sector), substantia nigra, and five cortical gyri (medial frontal, rectus, cingulate, angular, medial temporal) were examined for senile plaques, neurofibrillary tangles, and Lewy bodies as well as for other possible neuropathology. Additional samples from striatum, pons, medulla oblongata, and cerebellum were also taken for neuropathological examinations.
Genomic DNA was extracted from whole blood or postmortem brain tissue by standard methods (QIAamp kits, Qiagen, USA). The I/D polymorphism of the DCP1 gene was detected using the protocol of Odawara et al, 14 where possible mistyping of the DCP1 *I/*D genotype as *D/*D was controlled by means of insertion specific primers and the inclusion of dimethyl sulphoxide in the PCR reaction. The amplification created restriction site method of Jensen et al 15 was used to identify the K variant of the BCHE gene. APOE 4 allele status was determined as described elsewhere. 16 The test for Hardy-Weinberg equilibrium was carried out using Arlequin (version 1.1, Schneider S, KueVer JM, Roessli D, and ExcoYer L, Genetics and Biometry Laboratory, University of Geneva, Switzerland, 1997). The genotype and allele frequencies of the DCP1 and BCHE genes were compared between cases and controls using the chisquare test. Multinomial logistic regression analysis (SPSS 9.0 for Windows, SPSS Inc, 1999) was used to investigate the risk of AD or PD produced by APOE 4 (one or two alleles) and DCP1 *I or DCP1 *D. A custom model was created to estimate interaction between 4 and DCP1 *I or DCP1 *D, taking as reference subjects who possessed neither 4 nor DCP1 *I ( 4−/DCP1 *I−) or DCP1 *D ( 4−/DCP1 *D−). The risk of AD or PD produced by 4 status/BCHE *WT or 4 status/BCHE *K combinations was analysed using the same approach. In view of the simultaneous comparisons, the correction factor n(m-1) (n loci with m alleles each) was applied to correct the significance level (p<0.008).
Results
The distributions of genotypes and alleles of the DCP1 I/D polymorphism in the AD, PD, PD(B+C), and control groups are presented in table 1. All groups were in Hardy-Weinberg equilibrium. The frequency of the DCP1 *I/*I and DCP1 *I/*D genotypes (DCP1 *I carriers) compared to the DCP1 *D/*D genotype (DCP1 *I non-carriers) was significantly higher in the AD group compared to controls (p=0.007). In the PD and PD(B+C) groups the frequencies of the genotypes and alleles of DCP1 I/D did not diVer significantly from those observed in the control group.
Calculation of an odds ratio (OR) for carriers of APOE 4, for carriers of DCP1 *I or DCP1 *D, and for those possessing 4 in combination with DCP1 *1 or DCP1 *D (subjects with neither 4 nor DCP1 *I or DCP1 *D as reference) (table 2), showed that the risk of AD was significantly increased for those who carried both DCP1 *I and 4 (OR 30.0, 95% confidence interval (CI) 7.3-123.7). The overall risk was greater than with either of these The distribution of genotypes of the BCHE WT/K polymorphism did not diverge significantly from Hardy-Weinberg equilibrium in any of the patient or control groups studied. The genotype and allele frequencies of this polymorphism in AD, PD, and PD(B+C) patients did not diVer significantly from those found in controls (table 3) . No increased risk of AD, PD, or PD with AD pathology resulting from interaction between 4 and BCHE *K could be observed, taking as reference subjects who carried neither of the alleles (table 4) . Since all 4 non-carriers had at least one BCHE *WT allele, the risk of AD or PD for subjects possessing BCHE *WT in combination with 4 could not be estimated. In contrast, investigation of the influence of the BCHE *WT/*WT genotype and APOE 4 allele status on the risk of AD showed a significantly increased risk of the disease in patients with both the BCHE *WT/*WT genotype and 4, taking as reference subjects who had neither this BCHE genotype nor 4. The OR for developing AD was calculated as 9.9 (95% CI 2.9-33.8, p<0.0001). APOE 4 and the BCHE *WT/*WT genotype alone gave an OR of 6.5 (95% CI 1.6-26.4, p=0.009) and 1.3  (95% CI 0.4-4.1, p=0.695) , respectively. In the PD and PD(B+C) groups, no significantly increased risk was observed for the 4+/BCHE *WT/*WT+ combination (data not shown).
Discussion
In the present study, we found evidence that interaction between DCP1 *I and 4 significantly increases the risk of AD compared to the situation in subjects without the two alleles. In PD, interaction between DCP1 *I and 4 could also be observed, but the association with the disorder was restricted to PD cases with histological findings suggestive or indicative of AD, which lends further support to the view that the DCP1 I/D polymorphism may be of importance in the development of AD neuropathology.
Our finding that the DCP1 *I carrier frequency was significantly increased in the Finnish late onset sporadic AD group compared to controls is in agreement with that of Kehoe et al, 8 who reported a similar association between DCP1 I/D and AD in the British population. Alvarez et al 17 found the increased DCP1 *I carrier frequency of a Spanish AD group not to diVer significantly from that in controls, but saw a significantly increased frequency of the DCP1 *I allele in AD patients over controls. In contrast, no association between DCP1 I/D and AD was observed in Israeli 18 or Italian 19 subjects, whereas in another Italian sample the DCP1 *D allele was found to be implicated in this disorder. 20 In the present investigation, the genotyping of the DCP1 I/D polymorphism was carried out using the method of Odawara et al, 14 the most accurate PCR based technique for the purpose. In some studies, identification of the heterozygous DCP1 *I/*D genotype as the homozygous *D/*D genotype may have been a source of inaccurate results, since such mistyping has been found to occur frequently when earlier modifications of DCP1 I/D genotyping were used. 14 The mechanism whereby the DCP1 I/D polymorphism could contribute to the development of AD pathology remains obscure. Since the polymorphism is located within an intron, it is conceivable that the DCP1 *I allele is not a genetic factor predisposing to AD, but exists in linkage disequilibrium with a variant elsewhere in the DCP1 gene or with a locus nearby. Further, if the finding that DCP1 *D constitutes a risk factor for AD in some populations is confirmed, this again suggests that the DCP1 I/D polymorphism is not a susceptibility factor in the disease. The role of the WT/K polymorphism of BCHE in the development of AD is unclear. The initial report by Lehmann et al, 10 where white British subjects were studied, suggested that the K variant of the BCHE gene and APOE 4 interact, increasing the risk of late onset AD. Their finding has been replicated in investigations in western Australian patients, 21 white Canadians, 22 and again in white British subjects, 23 while studies on patients from eastern Finland 24 and white Australians 25 have found evidence that the K variant could have a protective eVect against AD. The majority of investigations [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] so far have, however, failed to establish an association between BCHE WT/K and AD. In the present study, subjects possessing the BCHE *WT/*WT genotype in combination with APOE 4 were observed to run an increased risk of the disease compared to those having neither this BCHE genotype nor 4. Considering the role BCHE might have in the development of AD, for example, in the maturation process of senile plaques, 36 37 and the fact that BCHE*K produces a marked reduction in BCHE enzyme activity, the BCHE *WT allele, but not the K variant, could be expected to be implicated in AD. According to Singleton et al, 11 BCHE WT/K may also have a role in the development of PD, but we found no evidence to support this.
Lehmann et al 10 reported that the eVect of the K variant on the risk of AD was seen more clearly in a subgroup of patients with an age at disease onset exceeding 75 years. One explanation for the contradictory results obtained in studies on the role of the BCHE WT/K polymorphism in AD could therefore be failure to analyse a specific and narrower onset age stratum, leaving some of the eVects of the polymorphism on the risk of AD undetected (as, for example, in the present study owing to unavailability of the exact age at onset for all AD cases). The BCHE WT/K polymorphism may also exist in linkage disequilibrium with another nearby locus which is the actual susceptibility factor. DiVerences in the strength of this linkage disequilibrium in diVerent populations could explain conflicting findings regarding the role of the K variant in AD. The data of Brindle et al 26 did not, however, support this hypothesis.
In conclusion, our data showed that in Finns interaction between DCP1 *I and 4 increased the risk of AD as well as that of PD with coexisting AD pathology, whereas the wild type BCHE genotype in combination with 4 increased the risk of AD. The possibility exists, however, that the variants of the DCP1 I/D and BCHE WT/K polymorphisms identified here as being associated with AD and PD with concomitant AD pathology are in fact not susceptibility factors but are in linkage disequilibrium with such factors present elsewhere in these genes or in loci in their proximity.
